| abstract |
The present invention relates, inter alia, to compounds of formula I, and pharmaceutically acceptable salts or solvates thereof, and analgesic pharmaceutical compositions containing them, wherein D is a 5-8 membered cycloalkyl, a 5-8 membered heterocyclic or a 6 membered aromatic or heteroaromatic group. ; n is 0, 1, 2 or 3; A, B, and Q are each independently hydrogen, C 1-10 alkyl, C 3-12 cycloalkyl, C 1-10 alkoxy, C 3-12 cycloalkoxy, -CH 2 OH, -NHSO 2, hydroxy (C 1-10 alkyl) -. , aminocarbonyl, (C 1 -C 4 alkyl) aminocarbonyl, di (C 1 -C 4 alkyl) aminocarbonyl, acylamino, acylaminoalkyl, amide or sulfonylamino (C 1 -C 10 alkyl), or AB together with a C 2 -C 6 carbon atom a bridge, or BQ together, can form a C3-C7 bridge, or A-Q together can form a C1-C5 bridge; Z is a bond, linear or branched C1-C6 alkylene, -NH-, -CHO-, -CH2NH-, -CH2N (CH3) -, -NHCH2-, -CH2CONH-, -NHCH2CO-, CH2CO-, -COCH2 -, -CH 2 COCH 2 -, -CH (CH 3) -, -CH =, -O- or -HC = CH, wherein the carbon and / or nitrogen atoms are unsubstituted or substituted with one or more halogen, lower alkyl, hydroxy or alkoxy groups They substituted; R 1 is hydrogen, C 1 -C 10 alkyl, C 3 -C 12 cycloalkyl, C 2 -C 10 alkenyl, amino, C 1 -C 10 alkylamino, C 3 -C 12 cycloalkylamino, -COOV 1, -C 1-4 COOV 1, cyano -, cyano (C 1 -C 10) alkyl, cyano (C 3 -C 10 cycloalkyl), NH 2 SO 2, NH 2 SO 2 (C 1 -C 4 alkyl), NH 2 SO (C 1 -C 4 alkyl), aminocarbonyl, (C 1 -C 4) alkyl) aminocarbonyl, di (C 1 -C 4 alkyl) aminocarbonyl, benzyl or C 3 -C 12 cycloalkenyl, monocyclic, bicyclic or tricyclic aryl or heteroaryl ring, heteromonocyclic ring, heterobicyclic ring system, wherein X is and wherein X is each independently is -NH-, -O-, -S-, or -CH 2 -; and wherein the alkyl, cycloalkyl, alkenyl, C 1 -C 10 alkylamino or C 3 -C 12 cycloalkylamino group or the benzyl group of R 1 is optionally halogen, hydroxy, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, nitro, trifluoromethyl, cyano, -COOV1-, -C1-4COOV1-, cyano (C1-C10alkyl) -, -C1-5 (= O) W1, -C1-5NHS (= O) 2W-, - C1-5NHS (= O) W1 is substituted with 1-3 groups independently selected from the group consisting of (5-membered heteroaromatic) (C1-C4 alkyl), phenyl, benzyl and benzyloxy, wherein the phenyl, benzyl, and abenzyloxy optionally substituted with 1-3 groups independently selected from halo, C 1-10 alkyl, C 1-10 alkoxy, and cyano; and the |